EVERSENS, S.L.

Founded in 2015 as a spin-off of the Public University of Navarra, at Eversens we develop innovative solutions based on breath analysis to help healthcare professionals and patients improve patient outcomes, thus contributing to the sustainability of the healthcare system. The analysis of exhaled biomarkers is a useful tool for the diagnosis, prognosis, and monitoring of various respiratory diseases, including asthma.
At Eversens we have a highly qualified and complementary human team, as well as the necessary facilities to manufacture our products, which are marketed either directly or through our distribution network.
In 2019 we launched our first product, evernoa base, a point of care (POC) device for measuring the Fraction of Exhaled Nitric Oxide (FeNO), portable, fast, highly accurate and easy to use. FeNO is a biomarker of airway inflammation that facilitates the diagnosis and monitoring of inflammatory respiratory diseases, such as asthma. What makes evernoa BASE unique compared to its competitors is the no need to inhale through the device, which improves hygiene and reduces the risk of cross-contamination, its first-rate performance and the ability to show results in such only 5 seconds in a very easy and intuitive way.
Aware of the limitations present in the current strategy for the management of patients with respiratory diseases, we have taken a step further, focusing our R&D efforts on the development of the evernoa system, a unique solution that will provide a holistic approach to address the problems of patients, professionals, pharmacies and health systems.